- Home
- CLLS vs MCN Comparison
CLLS vs MCN Comparison
Compare CLLS & MCN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- CLLS
- MCN
- Stock Information
- Founded
- CLLS 1999
- MCN 2004
- Country
- CLLS France
- MCN Canada
- Employees
- CLLS N/A
- MCN N/A
- Industry
- CLLS Biotechnology: Pharmaceutical Preparations
- MCN
- Sector
- CLLS Health Care
- MCN
- Exchange
- CLLS Nasdaq
- MCN Nasdaq
- Market Cap
- CLLS 148.1M
- MCN 135.8M
- IPO Year
- CLLS 2007
- MCN N/A
- Fundamental
- Price
- CLLS $1.53
- MCN $6.45
- Analyst Decision
- CLLS Buy
- MCN
- Analyst Count
- CLLS 3
- MCN 0
- Target Price
- CLLS $7.00
- MCN N/A
- AVG Volume (30 Days)
- CLLS 114.3K
- MCN 52.9K
- Earning Date
- CLLS 11-04-2024
- MCN 01-01-0001
- Dividend Yield
- CLLS N/A
- MCN 9.96%
- EPS Growth
- CLLS N/A
- MCN N/A
- EPS
- CLLS N/A
- MCN N/A
- Revenue
- CLLS $36,042,000.00
- MCN N/A
- Revenue This Year
- CLLS $387.77
- MCN N/A
- Revenue Next Year
- CLLS $11.14
- MCN N/A
- P/E Ratio
- CLLS N/A
- MCN N/A
- Revenue Growth
- CLLS 46.96
- MCN N/A
- 52 Week Low
- CLLS $1.41
- MCN $6.69
- 52 Week High
- CLLS $3.38
- MCN $8.60
- Technical
- Relative Strength Index (RSI)
- CLLS 45.06
- MCN 34.87
- Support Level
- CLLS $1.51
- MCN $6.42
- Resistance Level
- CLLS $1.62
- MCN $6.49
- Average True Range (ATR)
- CLLS 0.09
- MCN 0.05
- MACD
- CLLS 0.01
- MCN 0.01
- Stochastic Oscillator
- CLLS 29.17
- MCN 24.92
About CLLS Cellectis S.A.
Cellectis SA is a clinical stage biotechnological company, employing the core proprietary technologies to develop products based on gene-editing, with a portfolio of allogeneic Chimeric Antigen Receptor T-cells, or UCART, product candidates in the field of immuno-oncology and gene-edited hematopoietic stem and progenitor cells, or HSPC, product candidates in other therapeutic indications.
About MCN Madison Covered Call & Equity Strategy Fund
XAI Madison Equity Premium Income Fund is an investment management company. The Fund invests in an actively managed equity portfolio comprised of individual stocks and covered call options. The Fund's primary investment objective is to provide a high level of current income and gains, with a secondary objective of capital appreciation.